Bilateral ovarian masses, massive ascites, and prior appendectomy: must it be ovarian cancer? ——a case report of pseudomyxoma peritonei 24 years after appendectomy - Scorecard - MDSpire

Bilateral ovarian masses, massive ascites, and prior appendectomy: must it be ovarian cancer? ——a case report of pseudomyxoma peritonei 24 years after appendectomy

  • By

  • Sijie Feng

  • Shurui Yang

  • Kaixuan Yang

  • Xiuzhang Yu

  • Xiaoyu Niu

  • May 22, 2026

  • 0 min

Share

Clinical Scorecard: Bilateral Ovarian Masses and Significant Ascites Following Appendectomy: Is Ovarian Cancer Inevitable? — A Case Study of Pseudomyxoma Peritonei 24 Years Post-Appendectomy

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPatients with a history of appendectomy presenting with abdominal masses and ascites.
Care Setting

Key Highlights

  • PMP can present decades after appendectomy.
  • Intraoperative findings revealed yellow gelatinous material.
  • Pathology confirmed mucinous tumors of gastrointestinal origin.

Guideline-Based Recommendations

Diagnosis

  • Utilize imaging (CT scan) to assess for ascites and adnexal masses.
  • Consider tumor marker profiling for CA19-9, CA15-3, and CEA.

Management

  • Surgical intervention is necessary for definitive diagnosis and treatment.

Monitoring & Follow-up

  • Long-term follow-up is essential for patients with a history of appendectomy.

Risks

  • Misdiagnosis as ovarian cancer due to similar clinical presentation.

Patient & Prescribing Data

Female patients with a history of appendectomy presenting with abdominal symptoms.

Surgical exploration and pathology are critical for accurate diagnosis.

Clinical Best Practices

    Related Resources & Content

    Original Source(s)

    Bilateral ovarian masses, massive ascites, and prior appendectomy: must it be ovarian cancer? ——a case report of pseudomyxoma peritonei 24 years after appendectomy

    • by Sijie Feng, Shurui Yang, Kaixuan Yang, Xiuzhang Yu, Xiaoyu Niu

    • May 22, 2026

    Related Content

    Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma

    Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy

    Novel approaches for separating graft-versus-leukemia effects from graft-versus-host disease